{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:33:58Z","timestamp":1780450438725,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,5]]},"DOI":"10.7759\/cureus.46547","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T01:34:06Z","timestamp":1696556046000},"source":"Crossref","is-referenced-by-count":7,"title":["The Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Post Myocardial Infarction: A Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Sohny","family":"Kotak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warda","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marium","family":"Mehmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Sagreeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Karishma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirya","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Pirya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeria","family":"Saquib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anosh Aslam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45578","article-title":"Advancements in myocardial infarction management: exploring novel approaches and strategies","volume":"15","author":"Sachdeva P","year":"2023","unstructured":"Sachdeva P, Kaur K, Fatima S, et al.. Advancements in myocardial infarction management: exploring novel approaches and strategies. Cureus. 2023, 15:e45578. 10.7759\/cureus.45578","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021682","article-title":"Trends in premature mortality from acute myocardial infarction in the United States, 1999 to 2019","volume":"11","author":"Dani SS","year":"2022","unstructured":"Dani SS, Lone AN, Javed Z, et al.. Trends in premature mortality from acute myocardial infarction in the United States, 1999 to 2019. J Am Heart Assoc. 2022, 11:e021682. 10.1161\/JAHA.121.021682","journal-title":"J Am Heart Assoc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12618","article-title":"Left ventricular remodelling after ST-segment elevation myocardial infarction: sex differences and prognosis","volume":"7","author":"van der Bijl P","year":"2020","unstructured":"van der Bijl P, Abou R, Goedemans L, et al.. Left ventricular remodelling after ST-segment elevation myocardial infarction: sex differences and prognosis. ESC Heart Fail. 2020, 7:474-81. 10.1002\/ehf2.12618","journal-title":"ESC Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43977","article-title":"Individualizing medicinal therapy post heart stent implantation: tailoring for patient factors","volume":"15","author":"Mohamad T","year":"2023","unstructured":"Mohamad T, Jyotsna F, Farooq U, et al.. Individualizing medicinal therapy post heart stent implantation: tailoring for patient factors. Cureus. 2023, 15:e43977. 10.7759\/cureus.43977","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5114\/aic.2018.79867","article-title":"Left ventricular reverse remodeling in patients with anterior wall ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention","volume":"14","author":"Grabka M","year":"2018","unstructured":"Grabka M, Kocierz-Wo\u017anowska M, Wybraniec M, Turski M, Wita M, Wita K, Mizia-Stec K. Left ventricular reverse remodeling in patients with anterior wall ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention. Postepy Kardiol Interwencyjnej. 2018, 14:373-82. 10.5114\/aic.2018.79867","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer MA","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moy\u00e9 LA, et al.. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992, 327:669-77. 10.1056\/NEJM199209033271001","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009, 339:b2535. 10.1136\/bmj.b2535","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009, 62:e1-34. 10.1016\/j.jclinepi.2009.06.006","journal-title":"J Clin Epidemiol"},{"key":"ref9","unstructured":"RoB 2. a revised Cochrane risk-of-bias tool for randomized trials. (2023). https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.12.037","article-title":"Comparison of the efficacy and safety of sacubitril\/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction","volume":"143","author":"Rezq A","year":"2021","unstructured":"Rezq A, Saad M, El Nozahi M. Comparison of the efficacy and safety of sacubitril\/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2021, 143:7-13. 10.1016\/j.amjcard.2020.12.037","journal-title":"Am J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000932","article-title":"Effects of sacubitril\/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction","volume":"32","author":"Wang H","year":"2021","unstructured":"Wang H, Fu X. Effects of sacubitril\/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction. Coron Artery Dis. 2021, 32:418-26. 10.1097\/MCA.0000000000000932","journal-title":"Coron Artery Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000955","article-title":"Benefits of early administration of sacubitril\/valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention","volume":"32","author":"Zhang Y","year":"2021","unstructured":"Zhang Y, Wu Y, Zhang K, Ke Z, Hu P, Jin D. Benefits of early administration of sacubitril\/valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Coron Artery Dis. 2021, 32:427-31. 10.1097\/MCA.0000000000000955","journal-title":"Coron Artery Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2191","article-title":"Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics","volume":"23","author":"Jering KS","year":"2021","unstructured":"Jering KS, Claggett B, Pfeffer MA, et al.. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021, 23:1040-8. 10.1002\/ejhf.2191","journal-title":"Eur J Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054892","article-title":"Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction","volume":"144","author":"Docherty KF","year":"2021","unstructured":"Docherty KF, Campbell RT, Brooksbank KJ, et al.. Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation. 2021, 144:199-209. 10.1161\/CIRCULATIONAHA.121.054892","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-48. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer MA","year":"2021","unstructured":"Pfeffer MA, Claggett B, Lewis EF, et al.. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med. 2021, 385:1845-55. 10.1056\/NEJMoa2104508","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000527357","article-title":"The value of sacubitril\/valsartan in acute anterior wall ST-segment elevation myocardial infarction before emergency percutaneous coronary intervention","volume":"147","author":"Lin G","year":"2022","unstructured":"Lin G, Chen W, Wu M, Dai C, Xu K. The value of sacubitril\/valsartan in acute anterior wall ST-segment elevation myocardial infarction before emergency percutaneous coronary intervention. Cardiology. 2022, 147:479-85. 10.1159\/000527357","journal-title":"Cardiology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2017.53.10.2722396","article-title":"Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients","volume":"53","author":"Zaid Iskandar M","year":"2017","unstructured":"Zaid Iskandar M, Lang CC. Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients. Drugs Today (Barc). 2017, 53:545-51. 10.1358\/dot.2017.53.10.2722396","journal-title":"Drugs Today (Barc)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7840852","article-title":"Effects and safety of sacubitril\/valsartan for patients with myocardial infarction: a systematic review and meta-analysis","volume":"2022","author":"Liu L","year":"2022","unstructured":"Liu L, Ding X, Han Y, Lv J. Effects and safety of sacubitril\/valsartan for patients with myocardial infarction: a systematic review and meta-analysis. J Healthc Eng. 2022, 2022:7840852. 10.1155\/2022\/7840852","journal-title":"J Healthc Eng"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13677","article-title":"The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis","volume":"8","author":"Xiong B","year":"2021","unstructured":"Xiong B, Nie D, Qian J, et al.. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis. ESC Heart Fail. 2021, 8:4852-62. 10.1002\/ehf2.13677","journal-title":"ESC Heart Fail"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.21037\/apm-22-210","article-title":"Therapeutic effects and safety of early use of sacubitril\/valsartan after acute myocardial infarction: a systematic review and meta-analysis","volume":"11","author":"Zhang L","year":"2022","unstructured":"Zhang L, Yan K, Zhao H, Shou Y, Chen T, Chen J. Therapeutic effects and safety of early use of sacubitril\/valsartan after acute myocardial infarction: a systematic review and meta-analysis. Ann Palliat Med. 2022, 11:1017-27. 10.21037\/apm-22-210","journal-title":"Ann Palliat Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft052","article-title":"Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)","volume":"15","author":"McMurray JJ","year":"2013","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013, 15:1062-73. 10.1093\/eurjhf\/hft052","journal-title":"Eur J Heart Fail"},{"key":"ref23","article-title":"Sacubitril-valsartan","author":"Nicolas D","year":"2022","unstructured":"Nicolas D, Kerndt CC, Reed M. Sacubitril-valsartan. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2012.12.014","article-title":"Biomarkers and diagnostics in heart failure","volume":"1832","author":"Gaggin HK","year":"2013","unstructured":"Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013, 1832:2442-50. 10.1016\/j.bbadis.2012.12.014","journal-title":"Biochim Biophys Acta"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001421","article-title":"Effects of sacubitril-valsartan in patients with various types of heart failure: a meta-analysis","volume":"81","author":"Zhang H","year":"2023","unstructured":"Zhang H, Huetteman AT, Reyes EA, Appelbaum JS. Effects of sacubitril-valsartan in patients with various types of heart failure: a meta-analysis. J Cardiovasc Pharmacol. 2023, 81:434-44. 10.1097\/FJC.0000000000001421","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai AS","year":"2019","unstructured":"Desai AS, Solomon SD, Shah AM, et al.. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019, 322:1077-84. 10.1001\/jama.2019.12843","journal-title":"JAMA"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43882","article-title":"Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to mitigate cardiovascular risk in patients with diabetes","volume":"15","author":"Jyotsna F","year":"2023","unstructured":"Jyotsna F, Ahmed A, Kumar K, et al.. Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to mitigate cardiovascular risk in patients with diabetes. Cureus. 2023, 15:e43882. 10.7759\/cureus.43882","journal-title":"Cureus"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43279","article-title":"Deciphering the dilemma: anticoagulation for heart failure with preserved ejection fraction (HFpEF)","volume":"15","author":"Jyotsna F","year":"2023","unstructured":"Jyotsna F, Mahfooz K, Sohail H, et al.. Deciphering the dilemma: anticoagulation for heart failure with preserved ejection fraction (HFpEF). Cureus. 2023, 15:e43279. 10.7759\/cureus.43279","journal-title":"Cureus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42790","article-title":"Unlocking the potential of immunotherapy in cardiovascular disease: a comprehensive review of applications and future directions","volume":"15","author":"Jyotsna F","year":"2023","unstructured":"Jyotsna F, Ikram J, Nageeta F, et al.. Unlocking the potential of immunotherapy in cardiovascular disease: a comprehensive review of applications and future directions. Cureus. 2023, 15:e42790. 10.7759\/cureus.42790","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/194252-the-efficacy-of-angiotensin-receptor-neprilysin-inhibitor-versus-angiotensin-converting-enzyme-inhibitor-or-angiotensin-receptor-blocker-post-myocardial-infarction-a-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:49Z","timestamp":1707509269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/194252-the-efficacy-of-angiotensin-receptor-neprilysin-inhibitor-versus-angiotensin-converting-enzyme-inhibitor-or-angiotensin-receptor-blocker-post-myocardial-infarction-a-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.46547","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,5]]}}}